13 July 2021
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that Kieron Harbinson, Group Finance Director of the Company, has notified the Board that he will step down from his position after 19 years of service with the Company. The Board would like to thank Kieron for his many years of service and wish him all the luck his future endeavours.
Following a process to identify a replacement, the Company has agreed to appoint Chris Lea, ACA, as Chief Financial Officer. Chris is an experienced public markets CFO, having most recently held the position of Chief Financial Officer at IndigoVision Group plc (AIM: IND) and Finance Director at Superglass Holdings PLC (AIM: SPGH) before that.
Chris qualified as a chartered accountant with KPMG in 1992 and has extensive public company and private equity board level experience gained within multi-national, high growth and turnaround environments. Chris’ appointment will be effective as of 30 August 2021.
Colin King, Chief Executive Officer of the Company, said:
“I would like to personally thank Kieron for all the support and guidance he has provided me since I joined the Company, he has been a great servant to Omega and I wish him all the best in whatever he decides to do in the future. I would also like to welcome Chris Lea to Omega next month and look forward to working with him on the next phase of Omega’s exciting future”
The following information is disclosed about Christopher Paul Lea, age 54, pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:
|Current Directorships / Partnerships||Previous Directorships / Partnerships held in the past 5 years|
|N/A||IndigoVision Group Limited (formerly IndigoVision Group plc)|
|IndigoVision UK Limited|
|IndigoVision Australia Pty Limited|
|IndigoVision PTE Ltd|
|IndigoVision Solucoes de Seguranca Electronica Limitada|
|IndigoVision Video Security Solutions Limited|
|IndigoVision Security Systems (Shanghai) Co Ltd|
Mr. Lea does not currently hold any ordinary shares in the Company. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
|Omega Diagnostics Group PLC||Tel: 01259 763 030|
|Bill Rhodes, Interim Non-Executive Chairman |
Colin King, Chief Executive
|Kieron Harbinson, Group Finance Director|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash/Edward Whiley (Corporate Finance)|
|Alice Lane (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Lianne Cawthorne||Mob: 07584 391 303|